Drug Trial Radar · NCT01610336
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Apr 5, 2012
Primary completion
Jun 10, 2016
Study completion May 27, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 4, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study assessed the safety and efficacy of escalating doses INC280 when added to gefitinib in patients with lung cancer that were known to have dysregulation of the c-MET pathway and who had failed after benefiting on a prior treatment with either gefitinib or erlotinib.
Conditions
- Non-small Cell Lung Cancer
Interventions
INC280Drug
During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
GefitinibDrug
Gefitinib 250 mg taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Frequency of Dose Limiting Toxicities (DLTs)Time frame: Up to 215 weeks
- Phase II : Overall Response Rate (ORR)Time frame: Until disease progression, up to 60.8 weeks
Locations
31 sites in 14 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Auckland, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
East Bentleigh, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shanghai, Shanghai Municipality, China
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Koto Ku, Tokyo, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Maastricht, AZ, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Seocho Gu, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Tainan, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.